Reply
John B. Seal, Markus Selzner, George Loss – 29 June 2015
John B. Seal, Markus Selzner, George Loss – 29 June 2015
Russell H. Wiesner – 29 June 2015
Kin Pan Au, See Ching Chan, Kenneth Siu Ho Chok, Albert Chi Yan Chan, Tiffany Cho Lam Wong, William Wei Sharr, Chung Mau Lo – 29 June 2015 – Our aim was to study the long‐term outcomes of living donor liver transplantation using small‐for‐size (SFS) grafts. From July 2002 to July 2009, 233 patients received a right liver graft with a middle hepatic vein from a living donor in our center.
Lucia Carulli, Chiara Gabbi, Marco Bertolotti – 29 June 2015
Yuki Takamatsu, Yasuhito Tanaka, Satoru Kohgo, Shuko Murakami, Kamalendra Singh, Debananda Das, David J. Venzon, Masayuki Amano, Nobuyo Higashi‐Kuwata, Manabu Aoki, Nicole S. Delino, Sanae Hayashi, Satoru Takahashi, Yoshikazu Sukenaga, Kazuhiro Haraguchi, Stefan G. Sarafianos, Kenji Maeda, Hiroaki Mitsuya – 29 June 2015 – Certain nucleoside/nucleotide reverse transcriptase (RT) inhibitors (NRTIs) are effective against human immunodeficiency virus type 1 (HIV‐1) and hepatitis B virus (HBV).
Jean‐Michel Pawlotsky, Robert Flisiak, Shiv K. Sarin, Jens Rasenack, Teerha Piratvisuth, Wan‐Long Chuang, Cheng‐Yuan Peng, Graham R. Foster, Samir Shah, Heiner Wedemeyer, Christophe Hézode, Wei Zhang, Kelly A. Wong, Bin Li, Claudio Avila, Nikolai V. Naoumov, on behalf of the VITAL‐1 study team – 27 June 2015 – Alisporivir is a cyclophilin inhibitor with pan‐genotypic anti–hepatitis C virus (HCV) activity and a high barrier to viral resistance. The VITAL‐1 study assessed alisporivir as interferon (IFN)‐free therapy in treatment‐naïve patients infected with HCV genotype 2 or 3.
Lucía Barbier‐Torres, Naiara Beraza, Pablo Fernández‐Tussy, Fernando Lopitz‐Otsoa, David Fernández‐Ramos, Imanol Zubiete‐Franco, Marta Varela‐Rey, Teresa C. Delgado, Virginia Gutiérrez, Juan Anguita, Albert Pares, Jesús M. Banales, Erica Villa, Juan Caballería, Luis Alvarez, Shelly C. Lu, Jose M. Mato, María Luz Martínez‐Chantar – 25 June 2015 – Prohibitin‐1 (PHB1) is an evolutionarily conserved pleiotropic protein that participates in diverse processes depending on its subcellular localization and interactome.
AASLD/IDSA HCV Guidance Panel – 25 June 2015
Man Li, Albert Mennone, Carol J. Soroka, Lee R. Hagey, Xinshou Ouyang, Edward J. Weinman, James L. Boyer – 25 June 2015 – The intercellular adhesion molecule 1 (ICAM‐1) is induced in mouse liver after bile duct ligation (BDL) and plays a key role in neutrophil‐mediated liver injury in BDL mice. ICAM‐1 has been shown to interact with cytoskeletal ezrin‐radixin‐moesin (ERM) proteins that also interact with the PDZ protein, Na+/H+ exchanger regulatory factor 1 (NHERF‐1/EBP50). In NHERF‐1−/− mice, ERM proteins are significantly reduced in brush‐border membranes from kidney and small intestine.
AASLD/IDSA HCV Guidance Panel – 25 June 2015